↓ Skip to main content

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin

Overview of attention for article published in BMC Complementary Medicine and Therapies, June 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
Published in
BMC Complementary Medicine and Therapies, June 2015
DOI 10.1186/s12906-015-0710-8
Pubmed ID
Authors

Ye He, Jie Ding, Yan Lin, Juan Li, Yongguo Shi, Juan Wang, Ya Zhu, Keming Wang, Xuezhen Hu

Abstract

Breast cancer remains a major health problem worldwide, and is becoming increasingly resistant to traditional drug treatments. For instance, Adriamycin (ADR) is beneficial for the treatment of breast cancer. However, its wide application often leads to drug resistance in clinic practice, which results in treatment failure. Gambogenic acid (GNA), a polyprenylated xanthone isolated from the traditional medicine gamboge, has been reported to effectively inhibit the survival and proliferation of cancer cells. Its effects on ADR resistance have not yet been reported in breast cancer. In this study, we examined the ability of GNA to modulate ADR resiatance and the molecular mechanisms underlying this process using a cell based in vitro system. An MTT assay was used to evaluate the inhibitory effect of the drugs on the growth of MCF-7 and MCF-7/ADR cell lines. The effects of drugs on apoptosis were detected using Annexin-V APC/7-AAD double staining. The expression of apoptosis-related proteins and the proteins in the PTEN/PI3K/AKT pathway were evaluated by Western blot analysis. In the MCF-7/ADR cell lines, the IC50 (half maximal inhibitory concentration) of the group that received combined treatment with GNA and ADR was significantly lower than that in the ADR group, and this value decreased with an increasing concentration of GNA. In parallel, GNA treatment increased the chemosensitivity of breast cancer cells to ADR. The cell apoptosis and cell cycle anaysis indicated that the anti-proliferative effect of GNA is in virtue of increased G0/G1 arrest and potentiated apoptosis. When combined with GNA in MCF-7/ADR cell lines, the expression levels of the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome ten) and the apoptosis-related proteins caspase-3 and capsese-9 were significantly increased, while the expression of phosphorylated AKT was decreased. Our study has indicated a potential role for GNA to increase the chemosensitivity of breast cancer cells to ADR. This modulatory role was mediated by suppression of the PTEN/PI3K/AKT pathway that led to apoptosis in MCF-7/ADR cells. This work suggests that GNA may be used as a regulatory agent for treating ADR resistance in breast cancer patients.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 27%
Researcher 2 18%
Other 1 9%
Student > Master 1 9%
Student > Ph. D. Student 1 9%
Other 0 0%
Unknown 3 27%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 3 27%
Biochemistry, Genetics and Molecular Biology 1 9%
Agricultural and Biological Sciences 1 9%
Psychology 1 9%
Medicine and Dentistry 1 9%
Other 0 0%
Unknown 4 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#18,414,796
of 22,811,321 outputs
Outputs from BMC Complementary Medicine and Therapies
#2,512
of 3,630 outputs
Outputs of similar age
#190,832
of 264,930 outputs
Outputs of similar age from BMC Complementary Medicine and Therapies
#60
of 88 outputs
Altmetric has tracked 22,811,321 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,630 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,930 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.